DAFTAR PUSTAKA

Abergel R.P., Pizzurro D., Meeker C.A., *et al*. 1985. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. *J Invest Dermatol*. 84:384-8.

Akaishi S., Akimoto M., Ogawa R., *et al*. 2008. The relationship between keloid growth pattern and stretching tension: visual analysis using the finite element method. *Ann Plast Surg*. 60:445–451.

Alster T.S., Handrick C. 2000. Laser treatment of hypertrophic scars, keloids, and striae. *Semin Cutan Med Surg*. 19:287–292.

Alster T. 2003. Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. *Dermatol Surg*. 29:25–9.

Apikian M., Goodman G. 2004. Intralesional 5-fluorouracil in the treatment of keloid scars. *Australas J Dermatol*. 45:140–143.

Arima J., Ogawa R., Iimura T., *et al*. 2012. Relationship between keloid and hypertension. *J Nippon Med Sch*. 79:494–495.

Asilian A., Darougheh A., Shariati F. 2006. New combination of triamcinolone, 5-fluorouracil, and pulse-dye laser for treatment of keloid and hypertrophic scars. *Dermatol Surg*. 32: 907-912.

Atiyeh B.S., Costagliola M. and Hayek S.N. 2005. Keloid or Hypertrophic Scar: The Controversy: Review of the Literature. *Ann Plast Surg*. 54:676-680.

Atiyeh B.S. 2007. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. *Aesthetic Plast Surg*. 31:468–494.

Bagabir R., Byers R.J., Chaudhry I.H., *et al*. 2012. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. *Br J Dermatol*. 167:1053–1066.

Berman B., Viera M.H., Amini S., Huo R., Jones I.S. 2008. Prevention and management of hypertrophic scars and keloids after burns in children. *J Craniofac Surg*. 19(4): 989-1006.

Berridge M.V. and Tan A.S. 1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependance, and involvement of mitochondrial electron transport in MTT reduction. *Arch Biochem Biophy*. 303(2):474-482.

Bertheim U, Hellström S. 1994. The distribution of hyaluronan in human skin and mature, hypertrophic and keloid scars. *Br J Plast Surg*. 47:483–489.

Boyadjiev C., Popchristova E., Mazgalova J. 1995. Histomorphologic changes in keloids treated with Kenacort. *J Trauma*. 38:299–302.

Clark R.A.F. 1996. Wound repair: overview and general consideration. In: Clar RAF, ed. The Molecular and Cellular Biology of Wound Repair. *2nd ed*. New York:3–50.

Darougheh A., Asilian A., Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *Clin Exp Dermatol*. 34(2): 219-223.

Davidson S., *et al*. 2009. A primary care perspective on keloids. *Medscape J Med*. 11(1):18.

Davison S.P., Dayan J.H., Clemens M.W., Sonni S., Wang A., Crane A. 2009. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. *Aesthet Surg J*. 29:40-46.

de Oliveira G.V., Nunes T.A., Magna L.A., Cintra M.L., Kitten G.T., Zarpellon S., *et al*. 2001. Silicone versus nonsilicone gel dressings: A controlled trial. *Dermatol Surg*. 27:721-726.

Ehrlich H.P., Desmoulière A., Diegelmann R.F., *et al*. 1994. Morphological and immunochemical differences between keloid and hypertrophic scar. *Am J Pathol*. 145:105–113.

Fitzpatrick R.E. 1999. Treatment of inflamed hypertrophic scars using intralesional 5-FU. *Dermatol Surg*. 25(3):224–232.

Fong EP, Bay BH. 2002. Keloids—the sebum hypothesis revisited. *Med Hypotheses*. 58:264–269.

Friedman S.J., Butler D.R., Dittelkov M.R. 1988. Perilesional linear atrophy and hypopigmentation after intralesional cortocisteroid therapy. *J Am Acad Dermatol*. 19: 537-541.

Friedman D.W., Boyd C.D., Mackenzie J.W., Norton P., Olson R.M., Deak S.B. 1993. Regulation of collagen gene expression in keloids and hypertrophic scars. *J Surg Res*. 55:214-219.

Garner W.L. 1998. Epidermal regulation of dermal fibroblast activity. *Plast Reconstr Surg*. 102:135–139.

Gauglitz G.G., Korting H.C., Pavicic T., Ruzicka T., Jeschke M.G. 2011. Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. *Mol Med*. 17(1-2): 113-125.

Guix B., *et al*. 2001. Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. *Int J Radiat Oncol Biol Phys*. 50:167–172.

Gupta S., Sharma V.K. 2010. Standard guidelines of care: keloids and hyperthrophic scars. *Indian J Dermatol Venereol Leprol*. 77: 94-100.

Haq M.A., Haq A. 1990. Pressure therapy in treatment of hypertrophic scar, burn contracture and keloid: The Kenyan experience. *East Afr Med J*. 67:785-793.

Huang L., Wong Y.P., Cai Y.J., Lung I., Leung C.S., Burd A. 2010. Low-dose 5-fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. *Br J Dermatol*. 163:1181-1185.

Huang C., Akaishi S., Hyakusoku H., *et al*. 2012. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. *Int Wound J*.

Huang C., Murphy G.F., Akaishi S., Ogawa R. 2013. Keloids and hypertrophic scars: Update and future directions. *Plast Reconstr Surg Glob Open*. 1(4):25.

Huang L., Cai Y.J., Lung I., Leung B.C.S., Burd A. 2013. A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblast in vitro. *J Plast Reconstr Aesth Surg*. 66: 251-259.

Janssen de Limpens AM, Cormane RH. 1982. Studies on the immunologic aspects of keloids and hypertrophic scars. *Arch Dermatol Res*. 274:259–266.

Kelly A.P. 2004. Medical and surgical therapies for keloids. *Dermatol Ther*. 17:212–218.

Khan M.A., Bashir M.M., Khan F.A. 2014. Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *J Pak Med Assoc*. 64: 1003-1007.

Khoo Y.T., Ong C.T., Mukhopadhyay A., *et al*. 2006. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. *J Cell Physiol*. 208:336–343.

Kim D.Y., Kim E.S., Eo S.R., Kim K.S., Lee S.Y., Cho B.H. 2005. A surgical approach for earlobe keloid: Keloid fillet flap. *Arch Facial Plast Surg*. 7:172-175.

Kofford M.W., Schwartz L.B., Schechter N.M., *et al*. 1997. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. *J Biol Chem*. 272:7127–7131.

Kontochristopoulos G., Stefanaki C., Panagiotopoulos A., et al. 2005. Intralesional 5-fluorouracil in the treatment of keloids: AN open clinical and histopathologic study. *J Am Acad Dermatol*. 52: 474-481.

Kuo Y.R., Wu W.S., Jeng S.F., Wang F.S., Huang H.C., Lin C.Z., *et al*. 2005. Suppressed TGF-beta1 expression is correlated with upregulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. *Lasers Surg Med*. 36:38-44.

Lee J.Y., Yang C.C., Chao S.C., *et al*. 2004. Histopathological differential diagnosis of keloid and hypertrophic scar. *Am J Dermatopathol*. 26:379–384.

Leventhal D, Furr M, Reiter D. 2006. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. *Arch. Facial. Plast.Surg*. 8:362–8.

Louw L. 2007. The keloid phenomenon: progress toward a solution. *Clin Anat*. 20:3–14.

Marneros A.G., Norris J.E., Olsen B.R., *et al*. 2001. Clinical Genetics of Familial Keloids. *Arch Dermatol*. 137:1429-1434.

Marsh D.J., Pacifico M.D., Gault D.T. 2008. Keloids: When excision is the better part of valor. *Plast Reconstr Surg*. 121: 214-215.

Marshall N.J., Goodwin C.J., Holt S.J. 1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. *Growth Regul*. 5(2):69-84.

McCoy B.J., Cohen I.K. 1982. Collagenase in keloid biopsies and fibroblasts. *Connect Tissue Res*. 9:181-5.

Miller M.C., Nanchahal J. 2005. Advances in the modulation of cutaneous wound healing and scarring. BioDrugs. 19:363–381.

Moshref S.S.,Mufti S.T. 2010. Keloid and hyperthrophic scars: comparative histopathological and immunohistochemical study. JKAU: *Med Sci*., vol.17. 3: 3-22.

Moyer K.E., Saggers G.C., Ehrlich H.P. 2004. Mast cells promote fibroblast populated collagen lattice contraction through gap junction intercellular communication. *Wound Repair Regen*. 12:269–275.

Muneuchi G., Suzuki S., Onodera M., Ito O., Hata Y., Igawa H.H. 2006. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. *Scand J Plast Reconstr Surg Hand Surg*.40:111-116.

Mustoe T.A., *et al*. 2002. International clinical recommendations on scar management. *Plast Reconstr Surg*. 110:560–571.

Mustoe T.A. 2008. Evolution of silicone therapy and mechanism of action in scar management. *Aesthetic Plast Surg*. 32:82-92.

Mutalik S. 2005. Treatment of keloids and hypertrophic scars. *Indian J Dermatol Venereol Leprol*. 71:3–8.

Nakaoka H., Miyauchi S., Miki Y. 1995. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars. *Acta Derm Venereol*. 75:102–104.

Nanda S., Reddy B.S. 2004. Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg*. 30: 54-57.

Ogawa R., Mitsuhashi K., Hyakusoku H., Miyashita T. 2003. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. *Plast Reconstr Surg*. 111:547–555.

Peltonen J., Hsiao L.L., Jaakkola S., Sollberg S., Aumailley M., Timpi R. 1991. Activation of collagen gene expression in keloid: co-localization of type I and VI collagen and transforming growth factor-β1 mRNA. *J Invest Dermatol*. 97(2):240-248.

Phan T.T., *et al*. 2003. Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. *J Dermatol Sci*. 33:192–194.

Poochareon V.N., Berman B. 2003. New therapies for the management of keloids. *J Craniofac Surg*. 14:654–657.

Reish R.G., Eriksson E. 2008. Scar treatments: preclinical and clinical studies. *J Am Coll Surg*. 206:719–730.

Reno F., *et al*. 2003. In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. *Wound Repair Regen*. 11:331–336.

Rusciani L., Rossi G., Bono R. 1993. Use of cryotherapy in the treatment of keloids. *J Dermatol Surg Oncol*. 19:529-534.

Rossiello L., D'Andrea F., Grella R., *et al*. 2009. Differential expression of cyclooxygenases in hypertrophic scar and keloid tissues. *Wound Repair Regen*. 17:750–757.

Sadeghinia A., Sadeghinia S. 2012. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. *Dermatol Surg*. 38: 104-109.

Sharma S., Bassi R., Gupta A. 2012. Treatment of small keloids with intralesional 5-fluorouracil alone vs. intralesional triamcinolone acetonide with 5-fluorouracil. *J Pakistan Ass Dermatol*. 22: 35-40.

Slemp A.E., Kirschner R.E. 2006. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. *Curr Opin Pediatr*. 18:396–402.

Tang Y.W. 1992. Intra- and postoperative steroid injectioss for keloids and hypertrophic scars. *Br J Plast Surg*. 45:371.

Tuan T.L., Zhu J.Y., Sun B., Nichter L.S., Nimni M.E., Laug W.E. 1996. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. *J Invest Dermatol*. 106:1007-1010.

Ueda K., Furuya E., Yasuda Y., *et al*. 1999. Keloids have continuous high metabolic activity. *Plast Reconstr Surg*. 104:694–698.

Uitto J., Perejda A.J., Abergel R.P., *et al*. 1985. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. *Proc Natl Acad Sci U S A*. 82:5935–5939.

Uppal R.S., Khan Kakar S., Talas G., Chapman P., McGrouther D.A. 2001. The effects of a single dose of 5-fluorouracil on keloid scars: A clinical trial of timed wound irrigation after extralesional excision. *Plast Reconstr Surg*. 108: 1218-1224.

Verhaegen P.D., van Zuijlen P.P., Pennings N.M., *et al*. 2009. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. *Wound Repair Regen*. 17:649–656.

Wahl S.M., Wahl L.M., McCarthy J.B. 1978. Lymphocyte-mediated activation of fibroblast proliferation and collagen production. *J Immunol*. 121:942–946.